Abstract
Introduction: Depression is a very common psychological problem observed all around the world. Though various treatment modalities are available for this mental illness, further research is warranted to find novel therapeutics. Recent speculations on the role of adiponectin in animal models of depression have shown interesting results. Leptin is an adipokine that affects mood and cognition. Hence, the role of adiponectin and leptin in patients with depression needs to be probed. Objective: To estimate serum adiponectin and leptin concentration in depressive patients and compare them with healthy controls. Methods: This study was conducted at the Department of Biochemistry and Psychiatry, VMMC, and Safdarjung Hospital, New Delhi, following ethical clearance from our institution’s Ethics Committee. Serum samples were taken from 30 severely depressive patients and 30 healthy controls subsequent to receiving written consent from the patients’ relatives. The samples were checked for serum adiponectin and leptin levels via QUAEE-BIO and a DBC ELISA kit. Data were analyzed using SPSS version 21.0. Results: Cases and controls were age- and sex-matched. Serum adiponectin levels in the depression group were significantly higher than in the controls [Z = −2.18, p = 0.03]. Serum leptin levels in the depression group were not significantly different from that of the controls [Z = −0.47, p = 0.64]. Also, there was no correlation between serum adipokine levels and the severity of depression. However, there was a significant difference in adipokine levels between sexes in the case group and in the whole study group (p = 0.000). Conclusions: The higher serum adiponectin levels in the case group are in contrast with previous studies, which found lower adiponectin levels in depression. This may be due to the effect of treatment in cases of depression; further large-scale studies should be carried out to elucidate the role of adiponectin in depression. The small study size and absence of data about pretreatment serum adiponectin levels are the major limitations of this study.
Author Contributions
Conceptualization, D.S. and S.G.; methodology, D.S. and T.V.; software, D.S; validation, D.S., P.K.P. and T.V.; formal analysis, D.S. and P.K.P.; writing—original draft preparation, D.S. and P.K.P.; writing—review and editing, D.S., S.G., U.B. and K.K.; visualization, D.S.; supervision, K.K. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Approved by Institutional Ethical Committee. Ethical certificate number: IEC/VMMC/SJH/Project/December/2018-05.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data presented in this study are available on request from the corresponding author due to privacy concern of the patients.
Conflicts of Interest
The authors declare no conflicts of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).